Ocrelizumab shows promise in MS
Posted: Tue Nov 01, 2011 12:30 am
An investigational biologic drug that deactivates antibody-producing B cells reduced gadolinium-enhancing T1 lesions in multiple sclerosis patients, potentially offering yet another treatment approach to the disease, researchers said.
After 24 weeks of the phase II trial, lesion burden as measured by MRI was reduced by 89% in 55 patients treated with a low dose ocrelizumab relative to the 54-patient placebo group (95% CI 68% to 97%), according to Ludwig Kappos, MD, of University Hospital in Basel, Switzerland, and colleagues.
Lesions were reduced by 96% in 55 patients receiving a high dose of the drug (95% CI 89% to 99%), the researchers reported online in The Lancet.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397